ライフサイエンスコーパス: SMR

1 SMR at 10 years was higher until age 75 year, predominat

2 SMR can increase or decrease in response to food availab

3 SMR devices are unique in their ability to provide mass-

4 SMR due to cancer was 0.89 (95% CI 0.83 to 0.97).

5 SMR facilities are often confidential.

6 SMR facilities by compiling and matching the facility-re

7 SMR for cardiovascular disease was significant only in P

8 SMR increased when individuals were switched to a high f

9 SMR was 9.4 at 5 years and 5.4 at 10 years.

10 SMR was inversely related to baseline FVC% and increased

11 SMRs and EARs differed substantially by cause of death a

12 SMRs demonstrate spatial clustering of alterations in mo

13 SMRs due to cardiovascular diseases, suicide, infection

14 SMRs for cancer and liver disease (recurrent or transpla

15 SMRs ranged from 3.1 (95% CI, 2.1-4.3) for trauma to 8.7

16 SMRs reveal recurrent alterations across a spectrum of c

17 SMRs were broadly similar in different ethnic groups wit

18 SMRs were extracted.

19 SMRs were increased for cardiovascular disease (2.39; 95

20 SMRs were stratified for sex, age, and calendar period.

21 ath were those for heart disease (EAR, 15.1; SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitia

22 , 3.7; SMR, 13.1), and infections (EAR, 3.1; SMR, 2.2) after early-stage cHL.

23 ears in fast vs slow privatised towns: 1.13, SMR 0.83, 95% CI 0.77-0.88 vs 0.73, 0.69-0.77, respectiv

24 (expected deaths, 189; observed deaths, 141; SMR, 0.75; 95% CI, 0.63 to 0.88).

25 ut not for cancer (1.05; 95% CI, 0.95-1.17); SMRs increased with time.

26 tly increased in subjects living after 1965 (SMR, 1.27; 95% CI, 1.04-1.53; P=0.009) and aged >=60 yea

27 (expected deaths, 209; observed deaths, 242; SMR, 1.16; 95% CI, 1.02 to 1.31), but it was reduced amo

28 y examination (SIR, 0.32 [CI, 0.29 to 0.35]; SMR, 0.22 [CI, 0.18 to 0.25]).

29 Patients with 3+/4+ SMR enrolled in EVEREST II were stratified by non-high s

30 AEs) related to medications/drugs (EAR, 7.4; SMR, 5.0) after advanced-stage cHL and heart disease (EA

31 EAR, 15.1; SMR, 2.1), infections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR

32 anced-stage cHL and heart disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR, 13.1), and infections (EA

33 disease (EAR, 6.6; SMR, 1.7), ILD (EAR, 3.7; SMR, 13.1), and infections (EAR, 3.1; SMR, 2.2) after ea

34 ), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), and adverse events (AEs) related to medicati

35 ity, we solved X-ray crystal structures of a SMR transporter Gdx-Clo in complex with substrates to a

36 03-1.56) and in women 60 to 69 years of age (SMR, 1.94; 95% CI, 1.22-3.08).

37 Survival difference among SMR groups remained significant in 90-day conditional su

38 An SMR of 3.15 (95% CI 1.66-5.49) was obtained after using

39 rate (74.8 per 100,000 person-years) and an SMR of 2.4 (95% CI, 2.4-2.5).

40 rate (403.2 per 100,000 person-years) and an SMR of 3.6 (95% CI, 3.5-3.6).

41 were expected and 383 were observed, for an SMR of 0.96 (95% confidence interval [CI], 0.87 to 1.06)

42 lore this proposition, we are using Hsmr, an SMR from Halobacter salinarum that dimerizes to extrude

43 gle conservative mutation introduced into an SMR dimer is sufficient to change the resting conformati

44 as 1.62 (95% CI, 1.31-2.01) compared with an SMR in the CMV group of 0.76 (95% CI, 0.62-1.16).

45 as 2.00 (95% CI, 1.71-2.35) compared with an SMR in the CMV group of 0.85 (95% CI, 0.68-1.07).

46 rst-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29-1.73, respectively) relatives of

47 ond-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30-3.14, respectively) and first-co

48 and estimated the rate of change of CMR and SMR over the past 50 years.

49 ter high-quality colonoscopy did the SIR and SMR for 10.1 to 17.4 years of follow-up not differ compa

50 meta-analyses were used to summarize SIR and SMR for melanoma in any flight-based occupation.

51 Summary SIR and SMR of melanoma in pilots and cabin crew.

52 The highest overall SIR and SMR were estimated among survivors of laryngeal cancer (

53 .5 (95% CI, 30.2 to 46.0), respectively, and SMRs of 2,301 (95% CI, 1,652 to 3,122) and 30.2 (95% CI,

54 odeling evaluated association between annual SMR change and volume change over preceding years.

55 y correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with grea

56 sk patients and by short-term performance as SMR quintiles.

57 Cox model-based SMRs were computed with and without adjustment for patie

58 Because SMR is an intrinsic consequence of LV dysfunction, causa

59 equence of LV dysfunction, causality between SMR and mortality should not be implied.

60 In 26 of 36 studies reporting LV function by SMR grade, increasing SMR severity was associated with w

61 al understanding of substrate selectivity by SMR transporters is needed to identify the types of sele

62 Overall, cancer SMRs were 2.6 for patients on dialysis and 2.7 for trans

63 10 000 person-years) and gallbladder cancer (SMR, 3.82 [95% CI, 3.31-4.39]; mortality, 341 per 10 000

64 icipants who did not have surgery, all-cause SMR was 2.15 (95% CI, 2.11-2.20), which remained stable

65 All-cause SMR was 2.56 (95% CI 2.47 to 2.66) in males and 3.06 (95

66 Pooled all-cause SMR was 2.80 (95% CI 2.74 to 2.87).

67 Overall all-cause SMR was increased after surgery (1.94; 95% CI, 1.83-2.05

68 ophrenia were more than 3.5 times (all-cause SMR, 3.7; 95% CI, 3.7-3.7) as likely to die in the follo

69 s shelter during the study period (all-cause SMR: 1.35, 95% confidence interval (CI): 1.14, 1.59; dru

70 than the general population for all causes (SMR 5.7, 95% CI 5.5-5.8), particularly non-AIDS infectio

71 d CVD mortality occurred after chemotherapy (SMR, 1.36; 95% CI, 1.03 to 1.78; n=54) but not surgery (

72 rgan transplantation was higher in children (SMR, 84.61 [95% CI, 52.00-128.40]) and lower in patients

73 4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration in alcoholic liver dise

74 ralized SMR models outperformed conventional SMR models.

75 , 2.30-3.14, respectively) and first-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29

76 g HT at centers with superior (lower) 90-day SMR had longer graft survival (P for trend <0.001).

77 Adjusting for 90-day SMR was associated with 62% reduction in center variatio

78 also found to be elevated in second-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30

79 ity was highest in the year after diagnosis (SMR 24.3, 95% CI 23.4-25.2).

80 ricted to the first year after TC diagnosis (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascula

81 For patients on dialysis, SMRs were highest for multiple myeloma (30.5), testicula

82 c kidney disease did not result in different SMR.

83 n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45

84 R, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45; AER, 6.64; n=6).

85 infections (SMR 22-693) and kidney disease (SMR 13-45) across all indications, and from suicide in H

86 Particularly elevated SMRs were observed for chronic obstructive pulmonary dis

87 Strikingly elevated SMRs for ILD, infections, and AEs were observed < 1 year

88 alignant neoplasms (n = 1124) were excluded (SMR, 1.93 [95% CI, 1.75-2.13]).

89 In both FD and control fish, SMR was negatively correlated with preferred temperature

90 s using a shuttle-box, and then measured for SMR and AS at 10 degrees C, estimated by rates of oxygen

91 The optimal therapy for SMR is unclear.

92 Generalized SMR models outperformed conventional SMR models.

93 ree of SMR compared with patients not having SMR (21 studies, 21081 patients; RR, 1.96; 95% CI, 1.67-

94 e 23.1-9.2), hepatocellular carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR

95 1985-1999 to 2000-2010 in hepatitis C (HCV) (SMR change 23.1-9.2), hepatocellular carcinoma (HCC) (SM

96 We examine several cases with high SMR that are due to wildfire influence.

97 e processes and transplant expertise at high-SMR centers may improve short-term and overall survival

98 mone and corticosterone content, and highest SMR, and these trait values are least affected by pond d

99 ladder, and Hodgkin lymphoma had the highest SMRs ( > 5-10) through the follow up period.

100 rointestinal cancer patients had the highest SMRs (>2-5) through the follow up period.

101 We conclude that the identified SMR genes are part of a signaling cascade that induces a

102 ociated with 73% increased odds of improving SMR over time [odds ratio (OR) 1.73; 95% confidence inte

103 In SMR analyses of participants aged 50+, diabetes was sign

104 A reduction in SMR at cooler temperatures, coupled with a decrease in s

105 These shifts in SMR, in turn, were linked with individual differences in

106 Mutation frequencies in SMRs demonstrate that distinct protein regions are diffe

107 l mortality was not significantly increased (SMR, 1.06; 95% CI, 0.95-1.18; P=0.162).

108 porting LV function by SMR grade, increasing SMR severity was associated with worse LV function.

109 There was no association between individual SMR, or the tendency to obtain oxygen from air when in i

110 levated premature mortality from infections (SMR 22-693) and kidney disease (SMR 13-45) across all in

111 interval: 0.55, 2.51; 8 deaths) and kidney (SMR = 1.44; 95% confidence interval: 0.69, 2.65; 10 deat

112 t described for several PPR proteins lacking SMR motifs.

113 al: 0.69, 2.65; 10 deaths) and for leukemia (SMR = 1.48; 95% confidence interval: 0.77, 2.59; 12 deat

114 as increased risks for cancer of the liver (SMR = 1.27; 95% confidence interval: 0.55, 2.51; 8 death

115 olescent and young adult survivors had lower SMRs for death from health-related causes (ie, condition

116 ts from the GELA study and registry in Lyon (SMR, 1.09; P = .71).

117 ing for gains in fat-free mass and fat mass, SMR increased by 43 +/- 123 kcal/d more than expected (P

118 sed significantly in the total group of men (SMR, 1.27; 95% CI, 1.03-1.56) and in women 60 to 69 year

119 rved an excess of death due to mesothelioma (SMR = 2.24, 95% confidence interval (CI): 1.39, 3.42); n

120 SIR, 0.16 [CI, 0.13 to 0.20]) and mortality (SMR, 0.10 [CI, 0.06 to 0.14]) than low-quality examinati

121 ality ratios (SMRs) for all-cause mortality (SMR 1.14, 95% CI 0.65-1.85; p=0.67) or cancer-specific m

122 ng analysis showed overall excess mortality (SMR, 1.26; 95% CI, 1.07-1.48; P=0.003), driven by subjec

123 cant increase in suicide-specific mortality (SMR 6.85, 95% CI 2.22-15.98; p=0.002).

124 and from $3,200 to $7,100/kWe for a 225-MWe SMR.

125 estimates for a 45 megawatts-electric (MWe) SMR range from $4,000 to $16,300/kWe and from $3,200 to

126 Overall, noncancer SMRs were increased 2.4-fold (95% CI, 2.2 to 2.6; observ

127 ity racial differences in the computation of SMR helps to clarify disparities in quality of health ca

128 y increased in patients having any degree of SMR compared with patients not having SMR (21 studies, 2

129 substituted cations is a general feature of SMR transporters.

130 ary to quantify the environmental impacts of SMR hydrogen production alongside the use-phase of FCEVs

131 und considerable overlap with the results of SMR analyses performed with expression QTL (eQTL) data.

132 To clarify the role of SMR in the outcomes of patients with ischemic or idiopat

133 e requirements, high precision, and speed of SMR measurements, the method may become a valuable new t

134 The functional diversity of SMRs underscores both the varied mechanisms of oncogenic

135 CMRs and natural logarithm of SMRs were pooled by the method of the inverse of the var

136 its correlation with outcomes, mixed data on SMR and primary mitral regurgitation, studies not clearl

137 te publication data, studies lacking data on SMR grade and its correlation with outcomes, mixed data

138 ma that could be used to calculate an SIR or SMR in any flight-based occupation.

139 esults, our work suggests that SIM and other SMRs likely have a multivalent interaction with CYC/CDK

140 fidence interval (CI): 1.39, 3.42); no other SMRs were elevated overall.

141 Overall SMR for death before age 75 (premature mortality) was 5.

142 The overall SMR for all-cause mortality was 1.61 (95% CI 1.23-2.12;

143 n women with NF1 age < 40 years; the overall SMR for breast cancer was 5.20 (95% CI, 2.38 to 9.88).

144 The overall SMR was 2.4 (95% CI 1.7 to 3.3).

145 l similar to that of the general population (SMR 0.95, 95% CI 0.58-1.55) compared with those who were

146 evated compared with the Ontario population (SMR, 2.84 [95% CI, 2.61-3.07]).

147 o address this issue, we studied a maize PPR-SMR protein denoted PPR53 (GRMZM2G438524), which is orth

148 visit, those who had a lower-than-predicted SMR (basal EE) retained more of the fat gained during OF

149 ps, the small multidrug resistance proteins (SMRs), consists of proteins of about 110 residues that n

150 summary-data-based Mendelian randomization (SMR), a method developed to identify variants pleiotropi

151 ments for 8 wk, and sleeping metabolic rate (SMR) and 24-h sedentary energy expenditure (24h-EE) were

152 ch feeding history, standard metabolic rate (SMR) and aerobic scope (AS), interact to affect temperat

153 estimate individual standard metabolic rate (SMR) and the tendency to utilize aerial oxygen when alon

154 Flexibility in standard metabolic rate (SMR) may be particularly important since SMR reflects th

155 morphosis, increase standard metabolic rate (SMR), and elevate whole-body content of thyroid hormone

156 me to first SRE and skeletal morbidity rate (SMR).

157 age 15 years (standardized mortality ratio (SMR) = 2.00, 95% confidence interval (CI): 1.09, 3.35),

158 atio (SIR) and standardized mortality ratio (SMR) compared with those expected in the general populat

159 calculated the standardized mortality ratio (SMR) for COVID-19 comparing HIV positive vs. negative ad

160 exposure; and standardized mortality ratio (SMR) for suicide post-surgery.

161 years, and the standardized mortality ratio (SMR) of fatal heart disease is 2.24 (95% CI: 2.23-2.25).

162 years, and the standardized mortality ratio (SMR) of fatal stroke was 2.17 (95% CI, 2.15, 2.19).

163 years, and the standardized mortality ratio (SMR) of suicide was 4.44 (95% CI, 4.33, 4.55).

164 timates of the standardised mortality ratio (SMR) or hazard ratios associated with type 1 diabetes, e

165 A center-level standardized mortality ratio (SMR) was constructed (ratio of observed to expected deat

166 rtality rates, standardised mortality ratio (SMR), and hazard ratios (HR) for risk factors were estim

167 e ratio (SIR), standardized mortality ratio (SMR), or data on expected and observed cases of melanoma

168 mortality, and standardized mortality ratio (SMR).

169 ance by 90-day standardized mortality ratio (SMR; observed/expected mortality).

170 al population (standardized mortality ratio [SMR], 1.18; P = .25).

171 eater for men (standardized mortality ratio [SMR], 1.32 [95% CI, 1.18-1.48]) than for women (SMR, 1.1

172 dertaken, and standardised morbidity ratios (SMR) calculated, assessing morbidity prevalence relative

173 We estimated standardized mortality ratios (SMR) and used competing risks models to identify risk fa

174 nd calculated standardized mortality ratios (SMR) for kidney transplant centers over five distinct er

175 by analyzing standardized mortality ratios (SMR) in multigenerational pedigrees and in close relativ

176 Standardized morbidity ratios (SMRs) for 2013 were calculated, using the nondiabetic po

177 Standardized morbidity ratios (SMRs) were estimated by comparing the observed rates of

178 Comparative standardized mortality ratios (SMRs) and causes of death were obtained from the Office

179 ty risk using standardized mortality ratios (SMRs) and marginal structural modeling.

180 Standardized mortality ratios (SMRs) based on deaths through December 31, 2011, were ca

181 dised and sex-standardised mortality ratios (SMRs) for all-cause mortality (SMR 1.14, 95% CI 0.65-1.8

182 We calculated standardised mortality ratios (SMRs) for all-cause, suicide-specific, and cancer-specif

183 Standardized mortality ratios (SMRs) for CVD and absolute excess risks (AERs; number of

184 s (CMRs), and standardised mortality ratios (SMRs) in MS, and estimated the rate of change of CMR and

185 , age-and-sex-standardised mortality ratios (SMRs) in people with severe mental illness were increase

186 os (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative

187 Standardized mortality ratios (SMRs) reported by Medicare compare mortality at individu

188 We used standardized mortality ratios (SMRs) to compare cause-specific relative mortality risk

189 We calculated standardised mortality ratios (SMRs) to compare the mortality in the study populations

190 We used standardised mortality ratios (SMRs) to make comparisons with the general population.

191 andardized incidence-based mortality ratios (SMRs) using rates for the Norwegian population at large

192 os (SIRs) and standardized mortality ratios (SMRs) were calculated for selected cancer types.

193 al status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 inci

194 Standardised mortality ratios (SMRs) were estimated with age-specific, sex-specific, an

195 Standardized mortality ratios (SMRs) were used to assess the 5-year and 10-year excess

196 dels provided standardized mortality ratios (SMRs) with 95% confidence intervals (CIs).

197 record data, standardized mortality ratios (SMRs), relative SMRs (rSMRs), and proportional mortality

198 Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on di

199 essed them as standardised mortality ratios (SMRs).

200 ulation using standardized mortality ratios (SMRs).

201 ntry to yield standardized mortality ratios (SMRs).

202 os (SIRs) and standardized mortality ratios (SMRs).

203 nd mortality (standardised mortality ratios [SMRs] and mortality rates).

204 ey cancer (12.5); for transplant recipients, SMRs were highest for non-Hodgkin lymphoma (10.7), kidne

205 although the south Asian group had a reduced SMR for cancer mortality (0.49, 0.21-0.96).

206 In contrast, a reduced SMR with negligible CAMR and AHR was found in Rh/YIG hyb

207 ic cracker (FCC) and steam methane reformer (SMR) units, and alternative hydrogen production technolo

208 ogen production via steam methane reforming (SMR) is energy intensive, coproduces carbon dioxide, and

209 limiting regime (ELR) or slow motion regime (SMR).

210 ariably sized significantly mutated regions (SMRs).

211 function and secondary mitral regurgitation (SMR) are still controversial.

212 Secondary mitral regurgitation (SMR) occurs in the absence of organic mitral valve disea

213 ure (HF) and secondary mitral regurgitation (SMR).

214 ence interval (CI): 1.14, 1.59; drug-related SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related SMR: 1.54, 95

215 d SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related SMR: 1.54, 95% CI: 1.03, 2.21); all-cause and HIV-relate

216 vors had lower non-recurrent, health-related SMRs and relative risks of developing grade 3-5 chronic

217 % CI: 1.03, 2.21); all-cause and HIV-related SMRs in other patterns were not statistically significan

218 arbor a carboxy-terminal small-MutS-related (SMR) domain, but the functions of the SMR appendage are

219 the founding member of the SIAMESE-RELATED (SMR) family of plant-specific CDK inhibitor genes.

220 andardized mortality ratios (SMRs), relative SMRs (rSMRs), and proportional mortality ratios were cal

221 The Statistical Model Residual (SMR) can give information on additional sources of O3 th

222 , and used generalized spatial mark-resight (SMR) models to estimate puma population density across 1

223 porters from the small multidrug resistance (SMR) family drive the spread of multidrug resistance cas

224 The small multidrug resistance (SMR) family provides an ideal system to explore the role

225 e members of the small multidrug resistance (SMR) family that are composed of four transmembrane (TM)

226 , we use a suspended microchannel resonator (SMR) to measure single-cell density, volume, and passage

227 ibrils by suspended microchannel resonators (SMR).

228 Shear mode solidly mounted resonators (SMRs) are fabricated using an inclined c-axis ZnO grown

229 The respective SMRs in bipolar disorder were 6.47 (5.87-7.06) and 2.93

230 The mean (SD) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in th

231 ostructured morphology completely over 10 SE-SMR cycles due to its intrinsic lack of a support compon

232 Here, SE-SMR was studied using a mixture containing a Ni-hydrotal

233 ts with HF with moderate-to-severe or severe SMR were randomized to TMVr with the MitraClip plus guid

234 se prognosis in patients with HF with severe SMR.

235 members of the SIAMESE/SIAMESE-RELATED (SIM/SMR) class of cyclin-dependent kinase inhibitors were di

236 cific and strong activation of the three SIM/SMR genes in the meristems upon DNA stress, whereas over

237 Similarly, SMRs were calculated in parents of 128 present-day dilat

238 te (SMR) may be particularly important since SMR reflects the minimal energetic cost of living and is

239 rend in CMRs, all-cause, and gender-specific SMRs.

240 se variance weighting to obtain sex-specific SMRs and their pooled ratio (women to men) for all-cause

241 As such, SMR oligomerization sites should constitute viable targe

242 Summary SMR estimates for the International Classification of Di

243 The overall summary SMR of participants in any flight-based occupation was 1

244 The summary SMR for cabin crew was 0.90 (95% CI, 0.80-1.01; P = .97;

245 The summary SMR for pilots was 1.83 (95% CI, 1.27-2.63, P = .33; 4 r

246 95% CI, 1.03 to 1.78; n=54) but not surgery (SMR, 0.81; 95% CI, 0.60 to 1.07; n=50).

247 herapy) than did childhood cancer survivors (SMR 4.8 [95% CI 4.4-5.1] vs 6.8 [6.2-7.4]), which was pr

248 st meta-analysis to date to demonstrate that SMR, even when mild, correlates with adverse outcomes in

249 The SMR for cancer death after solid-organ transplantation w

250 The SMR for circulatory disease was increased at 2.72 (1.88-

251 The SMR for COVID-19 death associated with HIV was 2.39 (95%

252 The SMR for overall blindness in people with diabetes was si

253 The SMR for suicide after GBP was increased among females (n

254 The SMR in the early HFOV group was 1.62 (95% CI, 1.31-2.01)

255 The SMR in the HFOV group was 2.00 (95% CI, 1.71-2.35) compa

256 The SMR of the FD fish was increased compared with the contr

257 The SMR was significantly increased in those with a known re

258 rvivors (median age 42 years, IQR 34-50) the SMR compared to the general population for all-cause mor

259 ctured linker is likely conserved across the SMR family to play an active role in mediating the confo

260 ath, using Kaplan-Meier methodology, and the SMR based on mortality data from the Social Security Dea

261 this period the MDA8 reached 83 ppbv and the SMR suggests a wildfire contribution of 19 ppbv to the M

262 Significant improvement in the SMR emerged after 3 or more preceding years of increasin

263 An unanswered question in the SMR field is how the dimerization domain (TM4) is couple

264 lated (SMR) domain, but the functions of the SMR appendage are unknown.

265 ut is known in multidrug transporters of the SMR family, and is suggestive of an evolutionary anteced

266 The pooled women-to-men ratio of the SMR for all-cause mortality was 1.37 (95% CI 1.21-1.56),

267 -dependent transcriptional activation of the SMR genes was confirmed by different ROS-inducing condit

268 r transiency and improving estimation of the SMR home range parameter.

269 xtreme; the pooled women-to-men ratio of the SMR was 2.54 (95% CI 1.80-3.60).

270 arried out a structure-function study on the SMR protein EmrE using solid-state NMR spectroscopy in l

271 In schizophrenia, the SMR in those with lifetime substance use disorder was 8.

272 The SMRs for de novo cancer was 1.2 for patients on dialysis

273 The SMRs for female and male patients with RACU were 43.5 (9

274 onfidence interval: 1.27-1.53); however, the SMRs for ARMD, glaucoma, and cataract were not statistic

275 st in those individuals that depressed their SMR most.

276 owth; those individuals that increased their SMR more in response to elevated food levels grew fastes

277 hybrid, large spin-Hall magne toresistance (SMR) along with a sizable conventional anisotropic magne

278 een eQTLs and loci associated with CAD using SMR/HEIDI approach.

279 lize eGene and eJunction with SCZ GWAS using SMR and fine mapping.

280 r more preceding years of increasing volume (SMR change -0.008; 95% CI -0.015, -0.002; P = 0.01).

281 involve a large reactor and two light water SMRs.

282 When SMR was categorized as present or absent, all-cause mort

283 95% CI, 1.47-2.18; P < .001, I2 = 85%); when SMR was qualitatively graded, the incidence of all-cause

284 Finally, when SMR was quantitatively graded, it remained associated wi

285 of Thoracic Surgeons risk, 10.2+/-6.9%) with SMR underwent the MitraClip procedure.

286 valve repair (TMVr) in patients with HF with SMR.

287 as significantly higher in the patients with SMR (17 studies, 26359 patients; risk ratio [RR],1.79; 9

288 ar adjudicated outcomes of all patients with SMR undergoing the MitraClip procedure in the EVEREST II

289 reporting data on outcomes in patients with SMR were included.

290 efer temperatures that vary predictably with SMR and activity level, which are both plastic in respon

291 cause mortality in patients with and without SMR.

292 roke deaths than expected, especially women (SMR in females: 19.7 [95% confidence interval, 12.9-30.3

293 roke deaths than expected, especially women (SMR in females:19.7 [95%CI:12.9-30.3] and males: 9.1 [95

294 ], 1.32 [95% CI, 1.18-1.48]) than for women (SMR, 1.14 [95% CI, 0.80-1.63]).

295 ed with 2-fold increase in odds of worsening SMR over time (OR 2.14; 95% CI 1.07-4.26, P = 0.03).

296 imilar for those diagnosed aged 15-44 years (SMR = 1.06, 95% CI: 0.86-1.28), and lower for those diag

297 CI, 1.04-1.53; P=0.009) and aged >=60 years (SMR, 1.17; 95% CI, 1.01-1.35; P=0.02).

298 ) and lower in patients older than 60 years (SMR, 1.88 [95% CI, 1.62-2.18]) but remained elevated com

299 lower for those diagnosed aged 45-84 years (SMR = 0.81, 95% CI: 0.68, 0.95).

300 72]; incidence, 336 per 10 000 person-years; SMR, 4.56 [95% CI, 4.11-5.06]; mortality, 268 per 10 000